JOP20210060A1 - معدلات لمضاد تريبسين ألفا-1 - Google Patents

معدلات لمضاد تريبسين ألفا-1

Info

Publication number
JOP20210060A1
JOP20210060A1 JOP/2021/0060A JOP20210060A JOP20210060A1 JO P20210060 A1 JOP20210060 A1 JO P20210060A1 JO P20210060 A JOP20210060 A JO P20210060A JO P20210060 A1 JOP20210060 A1 JO P20210060A1
Authority
JO
Jordan
Prior art keywords
alpha
antitrypsin
modulators
aatd
compositions
Prior art date
Application number
JOP/2021/0060A
Other languages
Arabic (ar)
English (en)
Inventor
Yi Shi
Mary Elizabeth Eccles
Upul Keerthi Bandarage
Michael Aaron Brodney
Cavan Mckeon Bligh
Diane M Boucher
Michael John Boyd
Timothy Lewis Tapley
Qing Tang
Stephen A Thomson
Peter Jones
Jr Mac Arthur Johnson
Veronique Damagnez
Fanning Lev Tyler Dewey
Stefanie Roeper
Setu Roday
Rupa Sawant
Rebecca Jane Swett
Jinwang Xu
Barrantes Pedro M Garcia
Kevin James Gagnon
Jr Ronald Lee Grey
Simon Giroux
Jr Robert Francis Fimognari
Kevin Michael Cottrell
Sarathy Kesavan
Adam Looker
Brad D Maxwell
John Patrick Maxwell
Ales Medek
Mettachit Navamal
Philippe Marcel Nuhant
Joshua Kennedy Hussey
Amy Beth Hall
Sarah Carol Hood
Dennis James Hurley
Michael Waldo
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of JOP20210060A1 publication Critical patent/JOP20210060A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Peptides Or Proteins (AREA)
JOP/2021/0060A 2018-10-05 2019-10-04 معدلات لمضاد تريبسين ألفا-1 JOP20210060A1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862742148P 2018-10-05 2018-10-05
US201862768662P 2018-11-16 2018-11-16
PCT/US2019/054681 WO2020081257A1 (en) 2018-10-05 2019-10-04 Modulators of alpha-1 antitrypsin

Publications (1)

Publication Number Publication Date
JOP20210060A1 true JOP20210060A1 (ar) 2023-01-30

Family

ID=69467663

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0060A JOP20210060A1 (ar) 2018-10-05 2019-10-04 معدلات لمضاد تريبسين ألفا-1

Country Status (16)

Country Link
US (2) US11623924B2 (cg-RX-API-DMAC7.html)
EP (1) EP3860712A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022512588A (cg-RX-API-DMAC7.html)
KR (1) KR20210089656A (cg-RX-API-DMAC7.html)
CN (1) CN113164761A (cg-RX-API-DMAC7.html)
AU (1) AU2019362753A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021006392A2 (cg-RX-API-DMAC7.html)
CA (1) CA3114672A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021005884A2 (cg-RX-API-DMAC7.html)
IL (1) IL281884A (cg-RX-API-DMAC7.html)
JO (1) JOP20210060A1 (cg-RX-API-DMAC7.html)
MA (1) MA53827A (cg-RX-API-DMAC7.html)
MX (1) MX2021003819A (cg-RX-API-DMAC7.html)
TW (1) TW202024091A (cg-RX-API-DMAC7.html)
UY (1) UY38403A (cg-RX-API-DMAC7.html)
WO (1) WO2020081257A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20210060A1 (ar) 2018-10-05 2023-01-30 Vertex Pharma معدلات لمضاد تريبسين ألفا-1
GB201820450D0 (en) 2018-12-14 2019-01-30 Z Factor Ltd Compound and its use for the treatment of alpha1-antitryspin deficiency
US11884672B2 (en) * 2019-05-14 2024-01-30 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
TW202116303A (zh) * 2019-10-02 2021-05-01 美商維泰克斯製藥公司 α—1抗胰蛋白酶缺乏症之治療方法
GB201918413D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB201918414D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
GB201918416D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
GB201918410D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB201918404D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of aplha1-antitrypsin deficiency
AU2021247285A1 (en) 2020-04-03 2022-10-27 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
CN115697969B (zh) 2020-04-03 2026-08-11 弗特克斯药品有限公司 α-1抗胰蛋白酶调节剂
JP7732999B2 (ja) 2020-04-03 2025-09-02 バーテックス ファーマシューティカルズ インコーポレイテッド アルファ1-アンチトリプシンのモジュレーター
AU2021247282A1 (en) * 2020-04-03 2022-10-27 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
GB202009074D0 (en) 2020-06-15 2020-07-29 Z Factor Ltd Compound
EP4188931A2 (en) * 2020-07-27 2023-06-07 Vertex Pharmaceuticals Incorporated Processes for preparing modulators of alpha-1 antitrypsin
WO2022104353A1 (en) 2020-11-12 2022-05-19 Vertex Pharmaceuticals Incorporated Methods of monitoring alpha-1 antitrypsin (aat) deficiency by measuring polymerised aat
US20240002386A1 (en) * 2020-11-17 2024-01-04 Vertex Pharmaceuticals Incorporated Solid forms of 4-(5-(4-fluorophenyl)-6-(tetrahydro-2h-pyran-4-yl)-1,5-dihydropyrrolo[2,3-f]indazol-7-yl)benzoic acid
GB202108523D0 (en) 2021-06-15 2021-07-28 Z Factor Ltd Compositions and their use for the treatment of alpha1-antitrypsin deficiency
CN116813623A (zh) * 2022-03-21 2023-09-29 东南大学 一种吡咯并[2,3-f]吲唑类化合物的制备方法
CN114605385B (zh) * 2022-03-25 2023-09-08 河南大学 吲哚哌啶脲类trpv1拮抗/faah抑制双靶点药物及制备方法和应用
WO2025090827A1 (en) 2023-10-27 2025-05-01 Sub21, Inc. A1at modulators
WO2026014456A1 (ja) * 2024-07-10 2026-01-15 株式会社アークメディスン 化合物、補体d因子阻害剤、及び医薬組成物
WO2026136445A1 (en) 2024-12-17 2026-06-25 Sub21, Inc. A1at modulators

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790679A (fr) * 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
DK158590D0 (da) 1990-07-02 1990-07-02 Lundbeck & Co As H Indolderivater
JP2000072751A (ja) 1998-08-26 2000-03-07 Tanabe Seiyaku Co Ltd イソキノリノン誘導体
JP2000281654A (ja) 1999-03-26 2000-10-10 Tanabe Seiyaku Co Ltd イソキノリン誘導体
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
FR2802532A1 (fr) 1999-12-17 2001-06-22 Sanofi Synthelabo Derives de 2-phenyl-quinoleine, leur preparation et leur application en therapeutique
US6638929B2 (en) 1999-12-29 2003-10-28 Wyeth Tricyclic protein kinase inhibitors
CN1452619A (zh) 2000-07-26 2003-10-29 史密斯克莱·比奇曼公司 具有抗细菌活性的氨基哌啶喹啉和它们的氮杂等排的类似物
US20040176361A1 (en) 2001-05-23 2004-09-09 Masakazu Fujio Fused heterocyclic compound and medicinal use thereof
KR20050044450A (ko) 2001-11-14 2005-05-12 테바 파마슈티컬 인더스트리즈 리미티드 로사르탄 칼륨의 무정형 및 결정형 형태 및 이의 제조 방법
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
WO2009158587A1 (en) * 2008-06-26 2009-12-30 Inspire Pharmaceuticals, Inc. Method for treating pulmonary diseases using rho kinase inhibitor compounds
WO2011056222A1 (en) 2009-11-05 2011-05-12 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of treating disorders associated with protein aggregation
WO2011110852A1 (en) 2010-03-10 2011-09-15 Astrazeneca Ab Polymorphic forms of 6- [2- (4 -cyanophenyl) - 2h - pyrazol - 3 - yl] - 5 -methyl - 3 - oxo - 4 - (trifluoromethyl - phenyl) 3,4-dihydropyrazine-2-carboxylic acid ethylamide
US9572794B2 (en) 2014-08-06 2017-02-21 Vanderbilt University Substituted indoles as selective protease activated receptor 4 (PAR-4) antagonists
WO2016154051A1 (en) 2015-03-20 2016-09-29 University Of Florida Research Foundation, Inc. Combination therapy for treating infections diseases
CN109414596B (zh) 2016-05-12 2023-09-29 密歇根大学董事会 Ash1l抑制剂和用其进行治疗的方法
CN110546150B (zh) 2017-10-19 2021-12-21 江苏豪森药业集团有限公司 含吡唑基的三并环类衍生物、其制备方法和应用
JP7212693B2 (ja) 2017-11-01 2023-01-25 ブリストル-マイヤーズ スクイブ カンパニー ファルネソイドx受容体モジュレーターとしての架橋二環化合物
CN107698505A (zh) 2017-11-20 2018-02-16 孙婷婷 一种诺得司他的制备方法
CR20200263A (es) 2017-12-13 2020-07-26 Lupin Ltd Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5
CN111971278B (zh) 2018-01-31 2023-08-11 默克专利有限公司 用作irak抑制剂的喹啉化合物及其用途
CA3103920C (en) 2018-06-22 2025-09-16 Ucl Business Ltd COMPOUNDS FOR TREATING DISEASES MEDIATED BY ALPHA-1 ANTITRYPSIN
CA3108388A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
JOP20210060A1 (ar) 2018-10-05 2023-01-30 Vertex Pharma معدلات لمضاد تريبسين ألفا-1
CN110776459B (zh) 2019-03-19 2023-01-24 江苏知原药业股份有限公司 7-羟基-2-喹诺酮-二硫代氨基甲酸酯类胆碱酯酶抑制剂
US11884672B2 (en) * 2019-05-14 2024-01-30 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
TW202116303A (zh) 2019-10-02 2021-05-01 美商維泰克斯製藥公司 α—1抗胰蛋白酶缺乏症之治療方法
KR20220133227A (ko) 2020-01-30 2022-10-04 버텍스 파마슈티칼스 인코포레이티드 알파-1 항트립신 결핍증의 치료 방법
CA3177531A1 (en) 2020-04-03 2021-10-07 Vertex Pharmaceuticals Incorporated Indole derivatives as alpha-1 -antitrypsin modulators for treating alpha-1 -antitrypsin deficiency (aatd)
AU2021247282A1 (en) 2020-04-03 2022-10-27 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
AU2021247285A1 (en) 2020-04-03 2022-10-27 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
JP7732999B2 (ja) 2020-04-03 2025-09-02 バーテックス ファーマシューティカルズ インコーポレイテッド アルファ1-アンチトリプシンのモジュレーター
WO2021203007A1 (en) 2020-04-03 2021-10-07 Vertex Pharmaceuticals Incorporated Substituted 5-hydroxyindole compounds as modulators of alpha-1 antitrypsin
CN115697969B (zh) 2020-04-03 2026-08-11 弗特克斯药品有限公司 α-1抗胰蛋白酶调节剂
EP4188931A2 (en) 2020-07-27 2023-06-07 Vertex Pharmaceuticals Incorporated Processes for preparing modulators of alpha-1 antitrypsin

Also Published As

Publication number Publication date
BR112021006392A2 (pt) 2021-07-06
KR20210089656A (ko) 2021-07-16
JP2022512588A (ja) 2022-02-07
MX2021003819A (es) 2021-06-23
MA53827A (fr) 2021-09-15
TW202024091A (zh) 2020-07-01
AU2019362753A1 (en) 2021-05-20
CO2021005884A2 (es) 2021-05-20
EP3860712A1 (en) 2021-08-11
US11623924B2 (en) 2023-04-11
WO2020081257A1 (en) 2020-04-23
IL281884A (en) 2021-05-31
UY38403A (es) 2020-04-30
US20230265080A1 (en) 2023-08-24
US20210179587A1 (en) 2021-06-17
CA3114672A1 (en) 2020-04-23
CN113164761A (zh) 2021-07-23

Similar Documents

Publication Publication Date Title
MX2021003819A (es) Moduladores de alfa-1 antitripsina.
PH12022551522A1 (en) Smarca degraders and uses thereof
MX2025003987A (es) Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos
MX2021012216A (es) Degradadores de transductores de señal y activadores de transcripción (stat) y usos de los mismos.
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
PH12021500026A1 (en) Irak degraders and uses thereof
EP4438117A3 (en) Tyk2 inhibitors and uses thereof
EP3848370A3 (en) Tyk2 inhibitors and uses thereof
JOP20180039A1 (ar) مثبطات pd-1/pd-l1
WO2018195397A3 (en) Indole ahr inhibitors and uses thereof
WO2020252229A3 (en) Inhibitors of sarm1
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
EP4327809A3 (en) Tyk2 inhibitors and uses thereof
MX2018016038A (es) Compuestos y metodos para modular la funcion del acido ribonucleico (arn).
MX2018009773A (es) Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4).
MX2020001793A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
MX2021006674A (es) Composiciones para estabilizar bacterias y usos de las mismas.
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
CR20250103A (es) Moduladores de la alfa-1 antitripsina
EP4438124A3 (en) Methods for treating testicular and ovarian adrenal rest tumors
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
EP4650000A3 (en) High concentration formulation
EP3931336A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF LAMINOPATHIES
EP4616910A3 (en) Pcna inhibitors